TBI Medication Management on a Pharmacy Lien: Attorney Recovery Guide

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

Traumatic brain injury cases require anticonvulsants, stimulants, antidepressants, and anti-spasticity medications that document injury severity across multiple drug classes. Learn how each TBI drug class strengthens the demand package and how a pharmacy lien captures the full treatment record.

TBI Medication Management on a Pharmacy Lien: Attorney Recovery Guide

Traumatic brain injury (TBI) medication management involves four or more distinct drug classes — anticonvulsants, stimulants, antidepressants, and anti-spasticity agents — each treating a different dimension of brain injury and each independently documenting the severity and persistence of neurological damage. For personal injury attorneys, the TBI medication record is among the most powerful objective evidence available for demand packages because it demonstrates multi-system dysfunction that cannot be dismissed as subjective complaints.

• Anticonvulsants (levetiracetam, phenytoin) prescribed after TBI document the treating physician's assessment of seizure risk, which correlates directly with injury severity
• Stimulant medications (methylphenidate, amantadine) prescribed for cognitive deficits prove the patient has documented attention, processing speed, or arousal impairments
• Antidepressants and mood stabilizers reflect the neuropsychiatric consequences of brain injury — not pre-existing conditions — when the prescribing timeline follows the trauma
• Anti-spasticity agents (baclofen, tizanidine) confirm upper motor neuron damage and motor system involvement
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that organizes the multi-class TBI medication timeline into a single document for demand packages

Why TBI Cases Require Multi-Class Medication Protocols

A traumatic brain injury is not a single condition — it is a cascade of neurological disruptions that affect cognition, mood, motor function, sleep, and autonomic regulation simultaneously. According to James Wong, PharmD, founder of LienScripts, "The number of drug classes prescribed after a TBI is itself a measure of injury severity. A patient on four or five different medication categories is a patient with documented multi-system brain dysfunction."

The Centers for Disease Control and Prevention (CDC) estimates that TBI contributes to approximately 30% of all injury-related deaths in the United States, and even survivors of moderate-to-severe TBI face years of medication management. For attorneys, each drug class in the protocol represents a separate dimension of damages.

[!KEY] Each distinct drug class in a TBI medication protocol — anticonvulsant, stimulant, antidepressant, anti-spasticity — represents a separate neurological system affected by the injury. The breadth of the prescription profile is itself evidence of injury severity that defense experts cannot dismiss as subjective.

Anticonvulsants: Documenting Seizure Risk

Post-traumatic seizures are a recognized complication of TBI. The Brain Trauma Foundation guidelines recommend seizure prophylaxis with anticonvulsants for the first seven days after severe TBI, and many patients require ongoing anticonvulsant therapy for months or years.

Commonly prescribed anticonvulsants in TBI:

• Levetiracetam (Keppra) — the most frequently used first-line agent for post-traumatic seizure prophylaxis. FDA-approved for seizure disorders, with a favorable side-effect profile compared to older agents (FDA label, NDA 021035). Typical dosing: 500-1500 mg twice daily.
• Phenytoin (Dilantin) — historically the standard for acute post-traumatic seizure prophylaxis. Often used in the first seven days and then transitioned to levetiracetam for longer-term management.
• Valproic acid (Depakote) — used when seizures break through first-line therapy or when the patient has concomitant mood instability that valproate can address.
• Lacosamide (Vimpat) — a newer agent increasingly used as adjunctive therapy in refractory post-traumatic epilepsy.

What it signals in the case: Anticonvulsant prescriptions document that the treating physician assessed the TBI as severe enough to carry seizure risk. A patient on long-term levetiracetam is a patient whose brain injury was serious enough to warrant ongoing neurological monitoring.

[!TIP] Request pharmacy records showing the duration of anticonvulsant therapy. If levetiracetam continues beyond the standard seven-day prophylactic window, the treating neurologist has determined that the patient's seizure risk warrants extended or indefinite treatment — a strong indicator of significant structural brain injury.

Stimulants: Proving Cognitive Deficits

Cognitive dysfunction — impaired attention, processing speed, executive function, and arousal — is one of the most functionally devastating consequences of TBI. When a neurologist prescribes a stimulant medication, that prescription is a documented clinical finding of cognitive impairment.

Commonly prescribed stimulants and cognitive agents in TBI:

• Methylphenidate (Ritalin, Concerta) — the most studied stimulant for post-TBI cognitive deficits. A 2006 systematic review in the Journal of the International Neuropsychological Society found that methylphenidate improved attention and processing speed in TBI patients (PMID: 16903133).
• Amantadine — a dopaminergic agent that promotes arousal and cognitive recovery after TBI. The landmark NEJM study by Giacino et al. (2012) demonstrated that amantadine accelerated functional recovery in patients with disorders of consciousness after severe TBI (PMID: 22397877).
• Modafinil (Provigil) — used for post-TBI fatigue and excessive daytime sleepiness, which are common persistent symptoms even in moderate TBI.

Documentation value: A prescription for methylphenidate or amantadine in a post-TBI patient is not an ADHD diagnosis — it is a neurologist's clinical determination that the brain injury caused measurable cognitive deficits requiring pharmacological intervention.

Antidepressants: Neuropsychiatric Evidence, Not Pre-Existing

Depression, anxiety, irritability, and emotional lability after TBI are neuropsychiatric consequences of the brain injury itself — not pre-existing mood disorders. The prescribing timeline is the key evidence: when an antidepressant is first prescribed after the trauma, it documents a new condition caused by the injury.

Commonly prescribed antidepressants in TBI:

• Sertraline (Zoloft) — the most studied SSRI for post-TBI depression. A randomized controlled trial published in JAMA (2010) found sertraline effective for major depression after TBI (PMID: 21098252).
• Citalopram or escitalopram — SSRIs with minimal drug-drug interaction potential, preferred in patients on multiple medications.
• Trazodone — frequently prescribed at low doses (50-100 mg) for post-TBI insomnia and sleep-wake cycle disruption, which affects up to 70% of TBI patients.
• Venlafaxine (Effexor) — an SNRI used when SSRI therapy is insufficient or when the patient has comorbid neuropathic pain symptoms.

[!KEY] When defense counsel argues that depression or anxiety is a pre-existing condition, the pharmacy lien record showing a new antidepressant prescription initiated after the traumatic event — with no prior psychiatric medication history — is powerful rebuttal evidence. LienScripts medication timelines clearly show the first fill date relative to the injury date.

Anti-Spasticity Agents: Motor System Damage

Spasticity after TBI indicates damage to upper motor neuron pathways. Anti-spasticity medication documents motor system involvement that elevates the case from a "concussion" to a structural brain injury with motor consequences.

Commonly prescribed anti-spasticity agents in TBI:

• Baclofen — a GABA-B receptor agonist that acts at the spinal cord to reduce spasticity. Oral dosing ranges from 15-80 mg daily in divided doses. Severe cases may require intrathecal baclofen pump placement.
• Tizanidine (Zanaflex) — an alpha-2 agonist used for TBI-related spasticity, particularly when baclofen causes excessive sedation.
• Dantrolene (Dantrium) — acts peripherally at the muscle level; used when central-acting agents are insufficient or cause unacceptable CNS depression in a patient already impaired by TBI.

What it signals in the case: Anti-spasticity medication in a TBI patient documents that the brain injury affected descending motor pathways. As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "When you see baclofen or tizanidine prescribed after a head injury, the treating physician has identified upper motor neuron dysfunction — that is a catastrophic-level finding that separates these cases from simple concussions."

The Pharmacy Lien Advantage in TBI Cases

TBI patients commonly take four to eight medications simultaneously, creating a monthly medication burden that is unaffordable without insurance. A pharmacy lien through LienScripts removes this barrier entirely — every prescription is filled at zero upfront cost against the anticipated settlement.

Why the lien record matters for settlement:

• Multi-class evidence: Four or more drug classes prescribed simultaneously documents multi-system brain injury.
• Duration: TBI medication protocols lasting 12-24 months or longer prove the injury was not transient.
• Escalation patterns: Dose increases, medication switches, and addition of new drug classes over time demonstrate that the condition is worsening or failing to respond to standard treatment.
• Compliance documentation: Consistent fill dates prove the patient followed medical advice throughout recovery.

[!TIP] Request the full LienScripts dispensing record early in the case. The medication timeline — showing when each drug class was added, dose-adjusted, or discontinued — provides a roadmap of the patient's neurological trajectory that supplements neuropsychological testing and imaging.

How LienScripts Manages TBI Medication Liens

LienScripts coordinates with the treating neurologist, neuropsychiatrist, and primary care physician to ensure every TBI-related prescription is captured under the lien agreement. Because TBI patients often see multiple specialists who each prescribe different medication classes, centralized pharmacy lien management prevents gaps in the documentation.

The LienScripts MERIT (Medication Evaluation & Rationale for Injury Treatment) report organizes the full TBI medication history — anticonvulsants, stimulants, antidepressants, anti-spasticity agents, and any additional medications — into a pharmacist-signed clinical summary that attorneys can attach directly to demand packages.

Frequently Asked Questions